News & Updates

Show Multimedia Only

Plant-based fasting-mimicking diet does not boost medication response in UC

23 May 2025

The low-calorie, plant-based fasting-mimicking (LC-PB) diet does little to improve clinical response to medications in patients with active ulcerative colitis (UC), according to a study. However, LC-PB diet helps with steroid tapering and reduce serum amyloid A.

Plant-based fasting-mimicking diet does not boost medication response in UC

23 May 2025

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025 by

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.

Linerixibat quells cholestatic itch in PBC, enabling better sleep

23 May 2025

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025 by

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025 by

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025

Seladelpar benefit in PBC sustained at 3 years

22 May 2025 by

The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.

Seladelpar benefit in PBC sustained at 3 years

22 May 2025

Obesity ups risk of irritable bowel syndrome

21 May 2025

General and central obesity are both significant risk factors for the development of irritable bowel syndrome (IBS), suggests a study.

Obesity ups risk of irritable bowel syndrome

21 May 2025

Diet may influence CHF linked to gut microbiota

20 May 2025

An individual’s gut microbiota profile appears to be associated with chronic heart failure (CHF) risk factors, potentially mediated by microbial metabolites, results of a recent study have shown.

Diet may influence CHF linked to gut microbiota

20 May 2025

Higher alcohol withdrawal seen in acute pancreatitis patients living in vulnerable areas

20 May 2025

Patients with acute pancreatis who are residing in areas with higher Social Vulnerability Index (SVI) ranks are more likely to withdraw from alcohol use, according to a study.

Higher alcohol withdrawal seen in acute pancreatitis patients living in vulnerable areas

20 May 2025

Watch-and-wait approach feasible for therapy-responsive rectal cancer

19 May 2025

Survival outcomes do not differ between patients with locally advanced rectal cancer treated with mandatory total mesorectal excision (TME) and those on selective watch-and-wait (WW) strategies following total neoadjuvant therapy (TNT), reports a study.

Watch-and-wait approach feasible for therapy-responsive rectal cancer

19 May 2025

Linaclotide improves bowel symptoms in children with functional constipation

16 May 2025 by

Treatment with linaclotide led to significantly improved symptoms of incomplete bowel evacuation and straining in paediatric patients aged 6–17 years with functional constipation, according to a phase III study presented at DDW 2025.

Linaclotide improves bowel symptoms in children with functional constipation

16 May 2025

News & Updates

Filter by Specialty:

Specialty:

Plant-based fasting-mimicking diet does not boost medication response in UC

Plant-based fasting-mimicking diet does not boost medication response in UC

Linerixibat quells cholestatic itch in PBC, enabling better sleep

Linerixibat quells cholestatic itch in PBC, enabling better sleep

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

GLP-1RAs help reduce risk of gastrointestinal cancers

GLP-1RAs help reduce risk of gastrointestinal cancers

Seladelpar benefit in PBC sustained at 3 years

Seladelpar benefit in PBC sustained at 3 years

Obesity ups risk of irritable bowel syndrome

Obesity ups risk of irritable bowel syndrome

Diet may influence CHF linked to gut microbiota

Diet may influence CHF linked to gut microbiota

Higher alcohol withdrawal seen in acute pancreatitis patients living in vulnerable areas

Higher alcohol withdrawal seen in acute pancreatitis patients living in vulnerable areas

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Linaclotide improves bowel symptoms in children with functional constipation

Linaclotide improves bowel symptoms in children with functional constipation